Standard BioTools Inc. Increase (Decrease) in Other Current Liabilities
Standard BioTools Inc. (LAB) reported Increase (Decrease) in Other Current Liabilities of -$6.66 million for the 9-month period ending 2019-09-30, per its 10-Q filed 2019-11-08.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherCurrentLiabilities · last filed 2019-11-08
- Standard BioTools Inc. increase (decrease) in other current liabilities for the quarter ending 2019-09-30 was -$198.00K, a 110.23% decline year-over-year.
- Standard BioTools Inc. increase (decrease) in other current liabilities for the quarter ending 2019-06-30 was $2.74M, a 33.43% decline year-over-year.
- Standard BioTools Inc. increase (decrease) in other current liabilities for the quarter ending 2019-03-31 was -$9.21M.
- Standard BioTools Inc. increase (decrease) in other current liabilities for the quarter ending 2018-09-30 was $1.94M.
| Period end | Increase (Decrease) in Other Current Liabilities 3 month | Increase (Decrease) in Other Current Liabilities 6 month | Increase (Decrease) in Other Current Liabilities 9 month | Increase (Decrease) in Other Current Liabilities 9 month as first filed |
|---|---|---|---|---|
| 2019-09-30 | -$198.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $2.54M derived: sum of 2 quarters · filed 2019-11-08 | -$6.66M 10-Q · filed 2019-11-08 | |
| 2019-06-30 | $2.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | -$6.47M 10-Q · filed 2019-08-07 | ||
| 2019-03-31 | -$9.21M 10-Q · filed 2019-05-07 | |||
| 2018-09-30 | $1.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $6.05M derived: sum of 2 quarters · filed 2019-11-08 | $2.04M 10-Q · filed 2019-11-08 | |
| 2018-06-30 | $4.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $99.00K 10-Q · filed 2019-08-07 | ||
| 2018-03-31 | -$4.02M 10-Q · filed 2019-05-07 | |||
| 2017-09-30 | -$4.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | -$585.00K derived: sum of 2 quarters · filed 2018-11-06 | $687.00K 10-Q · filed 2018-11-06 | |
| 2017-06-30 | $3.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | $4.88M 10-Q · filed 2018-08-08 | ||
| 2017-03-31 | $1.27M 10-Q · filed 2018-05-08 | |||
| 2016-09-30 | -$4.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | -$3.64M derived: sum of 2 quarters · filed 2017-11-07 | -$1.30M 10-Q · filed 2017-11-07 | -$1.27M 10-Q · filed 2016-11-09 |
| 2016-06-30 | $492.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | $2.82M 10-Q · filed 2017-08-08 | ||
| 2016-03-31 | $2.33M 10-Q · filed 2017-05-09 | |||
| 2015-09-30 | -$2.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $887.00K derived: sum of 2 quarters · filed 2016-11-09 | -$3.44M 10-Q · filed 2016-11-09 | |
| 2015-06-30 | $3.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | -$999.00K 10-Q · filed 2016-08-09 | ||
| 2015-03-31 | -$4.33M 10-Q · filed 2016-05-09 | |||
| 2014-09-30 | -$619.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | $698.00K derived: sum of 2 quarters · filed 2015-11-09 | $146.00K 10-Q · filed 2015-11-09 | |
| 2014-06-30 | $1.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | $765.00K 10-Q · filed 2015-08-10 | ||
| 2014-03-31 | -$552.00K 10-Q · filed 2015-05-11 | |||
| 2013-09-30 | $1.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | $1.53M 10-Q · filed 2014-11-06 | ||
| 2013-06-30 | $108.00K 10-Q · filed 2014-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |